...
首页> 外文期刊>Mutation Research: International Journal on Mutagenesis, Chromosome Breakage and Related Subjects >Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature.
【24h】

Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature.

机译:子宫肉瘤体细胞突变的低频率:分子分析和文献综述。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The rarity of uterine sarcomas along with their pathological and molecular heterogeneities render their study particularly challenging. We evaluated a panel of somatic mutations principally centering on the tyrosine kinase gene family and their downstream signaling cascades in an attempt to identify potential candidate markers that may assist in diagnostic or therapeutic decisions in these tumors. METHODS: We performed mutational analysis of 20 exons from 9 genes (EGFR, CDKN2A, MET, KIT, RAS, BRAF, PI3KCA, HER-2 and PDGFR-alpha) on biopsy material from 25 patients who underwent primary surgery for uterine sarcoma between October 1995 and October 2003. Due to the limited number of studies conducted we have also undertaken a literature review of somatic mutations in uterine sarcomas. RESULTS: A total of 3 different somatic mutations were identified: one KRAS (codon G12D) in a carcinosarcoma and two exon 20 PI3KCA mutations (H1047R and H1047Y) both in carcinosarcomas. Mutational status of all mutations was confirmed using germline DNA extracted from peripheral blood. Consistent with the literature data, no other mutations regarding the rest of the genes of the panel were identified. Due to the low number of somatic mutations in our series, we did not perform further clinicopathological correlations. CONCLUSION: The absence of somatic mutations in the majority of genes that are considered critical in neoplastic transformation hampers the identification of potential therapeutic targets in patients with uterine sarcoma.
机译:目的:子宫肉瘤的罕见性及其病理和分子异质性使其研究特别具有挑战性。我们评估了一组主要集中于酪氨酸激酶基因家族及其下游信号传导级联的体细胞突变,以试图鉴定可能有助于这些肿瘤的诊断或治疗决策的潜在候选标记。方法:我们对来自10月之间接受子宫肉瘤初次手术的25例患者的活检材料的9个基因(EGFR,CDKN2A,MET,KIT,RAS,BRAF,PI3KCA,HER-2和PDGFR-alpha)的20个外显子进行了突变分析。 1995年和2003年10月。由于进行的研究数量有限,我们还对子宫肉瘤的体细胞突变进行了文献综述。结果:共鉴定出3种不同的体细胞突变:癌肉瘤中1个KRAS(密码子G12D)和癌肉瘤中2个外显子20 PI3KCA突变(H1047R和H1047Y)。使用从外周血中提取的种系DNA确认所有突变的突变状态。与文献数据一致,未鉴定出有关该组其余基因的其他突变。由于我们系列中的体细胞突变数量较少,因此我们没有进行进一步的临床病理学关联。结论:在肿瘤转化中被认为至关重要的大多数基因中都没有体细胞突变,这阻碍了子宫肉瘤患者潜在治疗靶标的确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号